Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations
Language English Country Netherlands Media print-electronic
Document type Journal Article, Review
PubMed
32763404
DOI
10.1016/j.ijbiomac.2020.07.274
PII: S0141-8130(20)34038-1
Knihovny.cz E-resources
- Keywords
- Anthracyclines, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Liposomes, Polymeric nanoformulations,
- MeSH
- Anthracyclines administration & dosage MeSH
- Chemistry, Pharmaceutical methods MeSH
- Humans MeSH
- Liposomes chemistry MeSH
- Neoplasms drug therapy MeSH
- Nanoparticles chemistry MeSH
- Polymers chemistry MeSH
- Antineoplastic Agents administration & dosage chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Anthracyclines MeSH
- Liposomes MeSH
- Polymers MeSH
- Antineoplastic Agents MeSH
Severe side effects and the rapid emergence of drug resistance in cancer cells are major problems in the chemotherapy utilizing anthracyclines, with a difference between cellular response at nano and micro scale levels. Understanding this situation is more complicated issue to attain efficient targeted formulations with low unexpected toxicity in patients. On nano-scale level, considering properties of nano-bio interaction in all relevant parts of the body may offer clue for suitable formulations. Four main strategies comprising PEGylation, surface charging, targeting, and stimuli responsiveness can be deployed to improve the liposomal and polymeric nanoformulations that can efficiently deliver common anthracyclines namely daunorubicin (DAU), doxorubicin (DOX), idarubicin (IDA), and epirubicin (EPI). Herein, the advances and challenges pertaining to the formulations of these anticancer drugs via liposomal and polymeric nanoformulations, are discussed.
References provided by Crossref.org
